Evidence map›Paper›PMID 33765902›Full record

SynthesisTherapeutic advances in respiratory disease

Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.

Roberto Ariel Abeldaño Zuñiga, Silvia Mercedes Coca, Giuliana Florencia Abeldaño, Ruth Ana María González-Villoria

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Roberto Ariel Abeldaño ZuñigaGuillermo Rojas Mijangos SN, Ciudad Universitaria, Miahuatlan de Porfirio Diaz, Oaxaca, 70800, Mexico.
Silvia Mercedes CocaPublic Health Research Institute, University of Sierra Sur, Miahuatlan de Porfirio Diaz, Oaxaca, Mexico.
Giuliana Florencia AbeldañoSchool of Medicine, University of Sierra Sur, Miahuatlan de Porfirio Diaz, Oaxaca, Mexico.
Ruth Ana María González-VilloriaPostgraduate Department, University of Sierra Sur, Miahuatlan de Porfirio Diaz, Oaxaca, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim was to assess the clinical effectiveness of drugs used in hospitalized patients with COVID-19 infection. We conducted a systematic review of randomized clinical trials assessing treatment with remdesivir, chloroquine, hydroxychloroquine, lopinavir, ritonavir, dexamethasone, and convalescent plasma, for hospitalized patients with a diagnosis of SARS-CoV-2 infection. The outcomes were mortality, clinical improvement, duration of ventilation, duration of oxygen support, duration of hospitalization, virological clearance, and severe adverse events. A total of 48 studies were retrieved from the databases. Eleven articles were finally included in the data extraction and qualitative synthesis of results. The meta-analysis suggests a benefit of dexamethasone

Indexed as

COVID-19 Drug TreatmentHospitalizationAntiviral AgentsHumansTreatment OutcomeAntiviral Agentsantiviralsclinical improvementCOVID-19drugsmortalitySARS-CoV-2

Identifiers

PMID33765902
PMCPMC8010807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.